The long-term trend of the EPS is an important number as it indicates the present value of ICad. The EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been -4.20 % over the last twelve months. Growth in EPS is an important measure of administration performance because it shows how much money ICad is making for it’s investors or shareholders.



ICad is part of the application software industry and is in the technology sector. The company CEO is Michael Klein. icad Inc is a provider of image analysis, work flow solutions and radiation therapy for early identification and treatment of cancer. The company has cancer detection and cancer therapy segments.

Previous Intraday Performance:

The ICAD shares had a previous change of -2.86% which opened at 4.13 and closed at 4.08. It moved to an intraday high of 4.19 and a low of 3.90.

SeekingAlpha:  AMBA, WDAY and VSLR among notable tech movers

Historical Performance:

Over the last five trading days, ICAD shares returned 24.77% and in the past 30 trading days it returned 31.61%. Over three months, it changed 41.18%. In one year it has changed 5.43% and within that year its 52-week high was 4.68 and its 52-week low was 2.43. ICAD stock is 68.25% above its 52 Week Low.

Our calculations result in a 200 day moving average of 3.20 and a 50 day moving average of 3.10. Right now, ICAD stock is trading 27.53% above its 200 day moving average.

SeekingAlpha:  AMBA, WDAY and VSLR among notable tech movers

Liquidity:

The company has a market cap of $68.4m with 16.8m shares outstanding and a float of 8.3m shares. Trading volume was 82,146 shares and has experienced an average volume of 89,679 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for ICad was -0.86 which ended on 31st of December 2017. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.08.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.06
06-30-2018:  -0.06
03-31-2018:  -0.19
12-31-2017:  -0.14



Indicators Also to Watch:

Based on the latest filings, there is 26.60% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.

I calculated the beta to be 0.84

PR Newswire:  Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -71.85%, return on assets is -31.84%, profit margin is -36.11%, price-to-sales is 2.65 and price-to-book is 7.21.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here